INTUNIV dosage forms and strengths

Revision as of 16:07, 25 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Guanfacine}} {{CMG}}; {{AE}} {{SS}} ==Dosage Forms and Strengths== 1 mg, 2 mg, 3 mg and 4 mg extended-release tablets<ref name="dailymed.nlm.nih.gov">{{Cite web ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Guanfacine
INTUNIV® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
TENEX® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Guanfacine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Dosage Forms and Strengths

1 mg, 2 mg, 3 mg and 4 mg extended-release tablets[1]


References

  1. "INTUNIV (GUANFACINE) TABLET, EXTENDED RELEASE INTUNIV (GUANFACINE) KIT [SHIRE US MANUFACTURING INC.]". Retrieved 25 February 2014.

Template:Antihyperkinetics